23andMe
About 23andMe
23andMe, founded in 2006, has transitioned from a pioneering direct-to-consumer (DTC) genetic testing company into a multifaceted genomics and biotechnology entity. Initially, it gained prominence for offering individuals insights into their ancestry and genetic predispositions through its Personal Genome Service (PGS). This service provides reports on ancestral origins, health risks, carrier conditions, and pharmacogenetic insights, with many of these reports meeting FDA requirements. The company has built an extensive research database, leveraging genetic and phenotypic data from millions of consented customers. This database has been a significant contributor to numerous peer-reviewed publications across various disease areas, including Parkinson’s disease, depression, COVID-19, and autoimmune diseases, and continues to support drug discovery efforts.
In a strategic move to expand its healthcare offerings, 23andMe acquired Lemonaid Health in late 2021, thereby integrating telehealth services and genetics-informed clinical care into its portfolio. This expansion included services like exome sequencing and comprehensive blood testing as part of its “Total Health” membership. However, the company faced significant financial challenges, leading to a Chapter 11 bankruptcy filing in March 2025. Following a contested auction, TTAM Research Institute, a nonprofit public benefit corporation founded by 23andMe co-founder Anne Wojcicki, acquired substantially all of 23andMe’s assets for $305 million on July 14, 2025.
Under the ownership of TTAM Research Institute, 23andMe continues to operate as a nonprofit. Its ongoing mission focuses on enabling individuals to access, understand, and benefit from the human genome, while also actively contributing to medical research and therapeutic development. The company’s offerings are designed to empower consumers to take a more active role in their health by providing genetic information that can inform discussions with healthcare providers regarding prevention, treatment, and healthy living.
Focus Areas
Business Intelligence
| Key Investors | GV (Google Ventures), NEA, Sequoia Capital, Founders Fund, Morningside, Fidelity Investments, Patrick Soon-Shiong |
| Partnerships | Mirador Therapeutics, Lifebit, California Northstate University |
| Acquisitions | Lemonaid Health (2021), CureTogether (2012) |
| Technology | SNP genotyping (Illumina Global Screening Array), AI/Machine Learning for disease prediction and health insights (DaNA AI assistant, Health Summary), multi-omics studies, cloud-native trusted research environment (with Lifebit) |
| FDA Clearances | multiple cleared products (estimated) |
What Physicians Need to Know
For physicians, 23andMe offers a unique patient-driven entry point into genetic insights. Patients may present with 23andMe reports on health predispositions, carrier status, or pharmacogenetics, which can serve as a valuable starting point for discussions about personalized health. The FDA-cleared reports provide a level of validation, but it's crucial to remember that 23andMe's tests are not diagnostic and do not cover all possible genetic variants. Physicians should use these reports to inform further clinical evaluation, confirmatory testing, or to guide preventative strategies and treatment discussions, especially concerning drug metabolism. The integration with telehealth services and the 'Total Health' offering with exome sequencing and clinician guidance can facilitate a more comprehensive, genetics-informed approach to patient care, allowing for deeper insights beyond standard genotyping.
23andMe's platform allows for the integration of genetic data with lifestyle and biomarker data, particularly through its AI assistant, DaNA, and partnerships like the one with Lark for AI-powered coaching programs. The acquisition of Lemonaid Health signifies a direct integration into telehealth and prescription services. For consumers, 23andMe also offers the ability to connect health records via Apple Health. The company's research arm actively collaborates with academic and pharmaceutical partners, providing access to its large de-identified genetic and phenotypic dataset for drug discovery and clinical trial recruitment.
What the Web Says
23andMe generally receives positive reviews for its ancestry and health reports, with many users finding the information insightful and easy to understand. However, there are recurring concerns about the accuracy of some ancestry breakdowns, particularly for non-European ethnicities, and the company's pricing model, which often involves additional subscriptions for comprehensive health insights. Employer reviews indicate a mixed bag, with appreciation for the brilliant minds and positive culture, but also criticisms regarding management, job security, and work-life balance.
Overall: MixedStrengths
- Detailed ancestry composition and haplogroups.
- Extensive health predisposition and carrier status reports.
- User-friendly app and website with regular updates.
- Ability to connect with DNA relatives.
- Commitment to scientific rigor and FDA authorization for many health reports.
- Good pay and benefits for employees, with some positions offering remote work flexibility.
Limitations
- Inconsistent accuracy in ancestry breakdowns, especially for non-European heritage.
- Additional subscriptions required for full health insights and advanced features.
- Health reports are informational and not suitable for clinical diagnosis.
- Concerns about data privacy, including data selling and breaches.
- Lack of robust family tree building tools compared to competitors.
- Mixed employee sentiment regarding management, job security, and work-life balance.
Based on reviews from: Reddit, Genomelink, Gene Food, YouTube, Indeed.com, Comparably, Thingtesting, Quora, Trustpilot, Live Science, Better Business Bureau
Last updated: 2026-07-17
Videos
News, demos, and interviews about 23andMe.
Videos load interactively. If none appear, search YouTube for 23andMe →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded 23andMe.
Comparisons
Related Companies
Intelligent Voice AI (IVAI) is an agentic AI platform that deploys AI voice agents specifically designed for healthcare, insurance, legal, and home services businesses. For physicians and medical practices, IVAI’s Evolve AI Agents act as an AI workforce, not just an answering service, handling a comprehensive range of administrative and operational tasks. These agents can […]
Dext, formerly known as Receipt Bank, is a company that specializes in bookkeeping automation, leveraging data, technology, and applied AI to enhance productivity and efficiency for businesses, accountants, and bookkeepers. [3, 16] Their platform is designed to streamline financial document management and automate bookkeeping tasks, aiming to simplify the accounting process and enable more informed […]
Cortex (https://www.cortex.app) is an AI-powered internal developer portal designed to enhance engineering excellence and streamline software development workflows. For physicians, this translates to a platform that can indirectly improve healthcare technology by enabling engineering teams to build more reliable, secure, and efficient software. The platform helps in cataloging, scoring, and assigning actions to improve service […]
Nino is an AI-powered financial planning and tax service that aims to provide comprehensive financial guidance. For physicians, Nino’s AI software can help manage income, student loans, and plan career transitions, such as moving from training to practice or considering practice ownership. The platform allows physicians to view loans, income, and savings in one place, […]
Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]
SamaCare is a healthcare AI company that provides a cloud-based workflow intelligence platform designed to streamline the prior authorization process for specialty medications. The company’s platform aims to reduce the administrative burden on medical practices, improve approval rates, and add predictability to patient care. By digitizing the often manual and paper-heavy prior authorization process, SamaCare […]